Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2010

View Archived Issues

GlaxoSmithKline updates progress of second quarter 2010

Ortho-McNeil-Janssen Pharma claims new gamma-secretase modulators

SAR-106881, an FGFR agonist derived from FGFR antagonists

New SGLT-2 inhibitor CSG-452 is selected as clinical candidate

Scientists present preclinical data on new HCV NS4A antagonists at ACS meeting

Enrollment complete in phase IIb trial of PEG-interferon lambda in hepatitis C

Somaxon and Procter & Gamble to copromote Silenor for insomnia

Omni Bio Pharm and UCD to begin preclinical study of AAT in influenza

Neuralstem files IND for phase I trial of stem cells in chronic spinal cord injury

Impax's phase III trial of IPX-066 in PD completes enrollment

Aoxing receives approval in China for buprenorphine/naloxone clinical trial

Avi BioPharma reports preclinical data on AVI-7100 for H1N1 influenza

FDA approves brand name Veletri for epoprostenol injection therapy for PAH

Pharmasset begins phase IIb trial of PSI-7977 in chronic hepatitis C

New hepatocyte growth factor receptor inhibitors claimed by sanofi-aventis

Cellceutix moves toward human trials of Kevetrin for drug-resistant cancer

Exelixis discovers new ceramide glucosyltransferase inhibitors

Rigel Pharmaceuticals presents new inhibitors of protein kinase C

New adenosylhomocysteinase inhibitors show preclinical potential to treat AD

FDA grants orphan status to LFB-R603 for chronic lymphocytic leukemia

Novartis purchases majority interest in Alcon from Nestle

FDA accepts pivotal phase III data for acyclovir Lauriad NDA

Pfizer discloses new inhibitors of diacylglycerol O-acyltransferase 2

Daiichi Sankyo launches Tribenzor in U.S.

Scientists generate functional dopaminergic neurons from human iPSCs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...